Therapy Area
NNRTI for the use as a vaginal formulation preventing HIV transmission and for the treatment of patients with HIV.
Competitive Edge
Fast and efficient inactivation of HIV and reduced risk of resistance developing than current NNRTI. Active against HIV mutants resistant to current NNRTI's.
Licensee Wuhan Humanwell Hi-Tech Industry Co. Ltd. has licensed MIV-160 for the Chinese market and is developing MIV-160 for many different application areas. Open for licensing for other markets.
